Lumakras Archives -

Mirati Therapeutics will hear from the FDA on its KRAS inhibitor adagrasib later this year, hoping to compete

Mirati heads for FDA verdict on KRAS drug with new data

https://pharmaphorum.com/news/mirati-heads-for-fda-verdict-on-kras-drug-with-new-data/

Novartis has joined the select cadre of drugmakers developing KRAS inhibitors for cancer, opening its account with phase

AACR: Novartis joins the KRAS clan, eyeing swift move to phase 3

https://pharmaphorum.com/news/aacr-novartis-joins-the-kras-clan-eyeing-swift-move-to-phase-3/

Armed with new clinical trial results, Amgen is expanding studies of its KRAS inhibitor Lumakras in pancreatic cancer,

Amgen eyes pancreatic cancer use for its pathfinder KRAS drug

https://pharmaphorum.com/news/amgen-eyes-pancreatic-cancer-use-for-kras-drug/

Amgen now has regulatory approval on both sides of the Atlantic for Lumykras, the culmination of many years

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

https://pharmaphorum.com/news/amgen-grabs-eu-approval-for-pathfinder-kras-drug-lumykras/

Amgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting

ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRC

https://pharmaphorum.com/news/esmo21-first-combo-data-with-amgens-lumakras-hit-the-mark-in-crc/

Lumakras